CA3124986C - Composes modulant la voie de la sphingosine pour le traitement de cancers - Google Patents

Composes modulant la voie de la sphingosine pour le traitement de cancers

Info

Publication number
CA3124986C
CA3124986C CA3124986A CA3124986A CA3124986C CA 3124986 C CA3124986 C CA 3124986C CA 3124986 A CA3124986 A CA 3124986A CA 3124986 A CA3124986 A CA 3124986A CA 3124986 C CA3124986 C CA 3124986C
Authority
CA
Canada
Prior art keywords
ozanimod
pharmaceutically acceptable
treatment
acceptable salt
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3124986A
Other languages
English (en)
Other versions
CA3124986A1 (fr
Inventor
Elazar Rabbani
James J. Donegan
Paul Diamond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Enzo Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/017,303 external-priority patent/US10675255B2/en
Application filed by Enzo Biochem Inc filed Critical Enzo Biochem Inc
Priority claimed from PCT/US2018/067131 external-priority patent/WO2020005313A1/fr
Publication of CA3124986A1 publication Critical patent/CA3124986A1/fr
Application granted granted Critical
Publication of CA3124986C publication Critical patent/CA3124986C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des méthodes et des compositions pour traiter des cancers et des troubles myéloprolifératifs à l'aide d'inhibiteurs de sphingosine kinase-1, tels que le SK1-I, et des agonistes sélectifs de récepteurs de la sphingosine-1-phosphate, tels que l'ozanimod.
CA3124986A 2018-06-25 2018-12-21 Composes modulant la voie de la sphingosine pour le traitement de cancers Active CA3124986C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/017,303 US10675255B2 (en) 2017-06-23 2018-06-25 Sphingosine pathway modulating compounds for the treatment of cancers
US16/017,303 2018-06-25
PCT/US2018/067131 WO2020005313A1 (fr) 2018-06-25 2018-12-21 Composés modulant la voie de la sphingosine pour le traitement de cancers

Publications (2)

Publication Number Publication Date
CA3124986A1 CA3124986A1 (fr) 2020-01-02
CA3124986C true CA3124986C (fr) 2026-05-05

Family

ID=

Similar Documents

Publication Publication Date Title
US20240024259A1 (en) Sphingosine pathway modulating compounds for the treatment of cancers
US20180085371A1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
Zhao et al. The clinical development of MEK inhibitors
JP7123806B2 (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
EP2309853A1 (fr) Procédés de régulation de la mitose cellulaire par inhibition de la phosphatase de sérine/thréonine
JP2017519019A (ja) ｍｄｍ２阻害剤の間欠投与
CN1681505A (zh) 用于治疗白血病的а ) N－{ 5－[ 4－( 4－甲基－哌嗪－1－基－甲基)－苯甲酰氨基]－2－甲基苯基}－4－( 3－吡啶基 ) －2－嘧啶－胺和b )组蛋白脱乙酰基酶抑制剂的组合
US11865105B2 (en) Sphingosine pathway modulating compounds for the treatment of cancers
AU2006311829B8 (en) Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies
WO2020005313A1 (fr) Composés modulant la voie de la sphingosine pour le traitement de cancers
US11931344B2 (en) Sphingosine pathway modulating compounds for the treatment of coronavirus infection
US20140213651A1 (en) Novel Use of Adapalene in Treating Cancer
JP2024523861A (ja) がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
EP1441717B1 (fr) Combinaison d'un inhibiteur atp competitif d'activite de kinase bcr/abl et analogue de tyrphostine
HK1193045B (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm